CA3257870A1 — Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
Assigned to GlaxoSmithKline Intellectual Property No 4 Ltd · Expires 2023-12-07 · 2y expired
What this patent protects
Disclosed herein are compounds of Formula: that inhibit DNA Polymerase Theta activity, in particular inhibit Pol activity by inhibiting ATP dependent helicase domain activity of Pol. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating…
USPTO Abstract
Disclosed herein are compounds of Formula: that inhibit DNA Polymerase Theta activity, in particular inhibit Pol activity by inhibiting ATP dependent helicase domain activity of Pol. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Pol such as cancer, including homologous recombination deficient cancers. Further disclosed herein are methods of using compounds of Formula or Formula that inhibit DNA Polymerase Theta activity in combination with a Poly ADP Ribose Polymerase inhibitor.
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.